JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

JNJ

227.25

-0.15%↓

UNH

370.37

+1.02%↑

TMO

465.89

-0.95%↓

ISRG

452.38

-3.02%↓

ABT

91.51

-2.44%↓

Search

Embecta Corp

Closed

SectorHealthcare

8.66 -3.88

Overview

Share price change

24h

Current

Min

8.66

Max

9.04

Key metrics

By Trading Economics

Income

18M

44M

Sales

-2.8M

261M

P/E

Sector Avg

3.915

67.147

Dividend yield

6.51

Profit margin

16.884

Employees

1,850

EBITDA

25M

96M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+88.26% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

6.51%

2.36%

Next Earnings

5 maj 2026

Next Dividend date

12 cze 2026

Next Ex Dividend date

27 maj 2026

Market Stats

By TradingEconomics

Market Cap

-101M

547M

Previous open

12.54

Previous close

8.66

News Sentiment

By Acuity

41%

59%

173 / 348 Ranking in Healthcare

Embecta Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

29 kwi 2026, 23:53 UTC

Earnings

Naver Posts Weaker First-Quarter Earnings

29 kwi 2026, 23:41 UTC

Hot Stocks

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 kwi 2026, 23:55 UTC

Earnings

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 kwi 2026, 23:54 UTC

Earnings

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 kwi 2026, 23:52 UTC

Earnings

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 kwi 2026, 23:51 UTC

Earnings

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 kwi 2026, 23:51 UTC

Market Talk

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 kwi 2026, 23:34 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 kwi 2026, 23:24 UTC

Earnings

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan 1Q Net CNY1.70B, Down 14%

29 kwi 2026, 23:22 UTC

Earnings

China Longyuan: Power Generation Down 2.9% as of End-March

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 kwi 2026, 23:20 UTC

Earnings

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 kwi 2026, 23:19 UTC

Earnings

China Vanke 1Q Loss Narrows>000002.SZ

29 kwi 2026, 23:18 UTC

Earnings

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 kwi 2026, 23:17 UTC

Earnings

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 kwi 2026, 23:15 UTC

Earnings

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 kwi 2026, 23:13 UTC

Earnings

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 kwi 2026, 23:12 UTC

Earnings

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 kwi 2026, 23:11 UTC

Earnings

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 kwi 2026, 23:04 UTC

Earnings

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 kwi 2026, 23:04 UTC

Earnings

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Peer Comparison

Price change

Embecta Corp Forecast

Price Target

By TipRanks

88.26% upside

12 Months Forecast

Average 17 USD  88.26%

High 22 USD

Low 12 USD

Based on 2 Wall Street analysts offering 12 month price targets forEmbecta Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

1

Buy

1

Hold

0

Sell

Sentiment

By Acuity

173 / 348 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Embecta Corp

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
help-icon Live chat